Immix Biopharma (NASDAQ:IMMX) Price Target Cut to $22.00 by Analysts at Mizuho

Immix Biopharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Mizuho cut its price target on Immix Biopharma from $23 to $22 but maintained an “outperform” rating; the new target implies about 210% upside from the prior close.
  • Analyst views are mostly positive: eight rate the stock Buy and one Sell, with a consensus “Moderate Buy” rating and a $24 average price target. HC Wainwright also raised its target to $27, while Needham raised its target to $30.
  • Shares traded at $7.10 on Wednesday. Immix reported quarterly EPS of -$0.19, in line with analyst expectations; its lead candidate is an investigational CAR T-cell therapy for relapsed or refractory AL amyloidosis.
  • Five stocks we like better than Immix Biopharma.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) had its target price dropped by analysts at Mizuho from $23.00 to $22.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Mizuho's target price suggests a potential upside of 209.77% from the company's previous close.

IMMX has been the topic of several other research reports. HC Wainwright raised their target price on shares of Immix Biopharma from $25.00 to $27.00 and gave the company a "buy" rating in a research note on Monday. Weiss Ratings reissued a "sell (d-)" rating on shares of Immix Biopharma in a research note on Thursday, October 15th. Needham & Company LLC increased their price objective on shares of Immix Biopharma from $21.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday, September 29th. Morgan Stanley reaffirmed an "overweight" rating on shares of Immix Biopharma in a report on Tuesday, October 20th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Immix Biopharma in a report on Wednesday, September 30th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Immix Biopharma has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

Check Out Our Latest Research Report on Immix Biopharma

Immix Biopharma Price Performance

Shares of IMMX stock traded down $0.10 on Wednesday, reaching $7.10. 109,027 shares of the stock were exchanged, compared to its average volume of 1,307,129. The stock has a market cap of $595.22 million, a PE ratio of -8.58 and a beta of 0.29. Immix Biopharma has a one year low of $3.78 and a one year high of $15.10. The stock has a 50 day moving average price of $9.57 and a 200 day moving average price of $9.60.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). On average, research analysts expect that Immix Biopharma will post -0.75 earnings per share for the current fiscal year.

Institutional Trading of Immix Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of IMMX. Jupiter Topco LLC bought a new stake in shares of Immix Biopharma in the 2nd quarter valued at $100,816,000. Janus Henderson Group PLC raised its stake in Immix Biopharma by 22.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company's stock worth $43,698,000 after buying an additional 880,434 shares during the period. BlackRock Inc. bought a new position in Immix Biopharma during the second quarter worth about $30,827,000. Opaleye Management Inc. bought a new position in Immix Biopharma during the second quarter worth about $24,177,000. Finally, Marshall Wace LLP lifted its holdings in Immix Biopharma by 3.3% during the third quarter. Marshall Wace LLP now owns 1,854,215 shares of the company's stock worth $19,284,000 after acquiring an additional 59,307 shares in the last quarter. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company's lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.

Further Reading

Analyst Recommendations for Immix Biopharma (NASDAQ:IMMX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immix Biopharma Right Now?

Before you consider Immix Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.

While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines